Home › Therapeutic areas › Neurology › Huntington's Disease
Huntington's Disease (5 companies)
Companies with an active program in Huntington's Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $796M | 6 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $6.55B | 29 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 2 | Approved | $1.91B | 11 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 1 | Approved | $1.52B | 4 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $665M | 5 |
No companies match.